Back to Journals » Journal of Receptor, Ligand and Channel Research » Volume 5

Liposome mitigation of curcumin inhibition of cardiac potassium delayed-rectifier current

Authors Helson L, Shopp, Bouchard, Majeed

Received 18 August 2012

Accepted for publication 23 September 2012

Published 16 November 2012 Volume 2012:5 Pages 1—8

DOI https://doi.org/10.2147/JRLCR.S37138

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Lawrence Helson,1 George Shopp,2 Annie Bouchard,3 Muhammad Majeed4

1SignPath Pharma, Quakertown, PA, USA; 2Shopp Nonclinical Consulting, Boulder, CO, USA; 3IPS Therapeutique Inc, Sherbrooke, Quebec, Canada; 4Sabinsa Inc, Princeton, NJ, USA

Background: The duration of the QT interval on the standard electrocardiogram (ECG) is measured from the beginning of the QRS complex (depolarization of the cardiac myocyte) to the end of the T-wave (completion of the repolarization phase of the cardiac myocyte). Repolarization is a result of currents generated by the outward flow of K+ through the K+ channels. Obstruction of ion flow in the channel leads to delayed repolarization, evidenced by a prolonged QT interval. Clinically, this is known as the long QT syndrome (LQTS), which, when expressed, can lead to severe cardiac arrhythmias and sudden death. Obstruction of K+ ion flow can result from gene mutations (eg, the human ether-a-go-go-related gene [hERG]) resulting in phenotypic abnormalities in K+ channels and/or common structurally diverse drugs. These gene abnormalities or drug-induced changes result in decreased cardiac delayed-rectifier K+ current (IKr, or KV11.1) in congenital or acquired LQTS, respectively. Increased risk of LQTS is a major drug development hurdle, and many drugs have been withdrawn during preclinical development, assigned black box warnings following approval, or withdrawn from the market. Autosomal recessive or dominant LQTS based upon 500 possible mutations in ten different genes coding for K+ channels has an incidence of 1:3000 or about 100,000 persons in the USA. Prolonged QT intervals or risk of LQTS occurs in 2.5% of the asymptomatic US population. The probability of cardiac death in patients with asymptomatic congenital LQTS who are concomitantly medicated with LQTS-inducing drugs appears to have increased.
Methods: E-4031 (methanesulfanalide), terfenadine (Seldane®), curcumin, liposomal curcumin, empty liposomes, empty liposomes vortexed with E-4031, or terfenadine and empty liposomes vortexed with curcumin were assayed for their effects on the K+-selective IKr tail current inhibition using human embryonic kidney (HEK 293) cells stably transfected with the hERG gene via the whole-cell manual patch clamp technique.
Results: E-4031, terfenadine, and curcumin inhibit IKr channel following nM-to-µM exposures. Empty liposomes had no effect on IKr. Both the liposomal curcumin formulation and vortexed mixtures of empty liposomes and curcumin prevented the IKr inhibitory effect of curcumin in a dose-dependent manner. Empty liposomes vortexed with E-4031 prevented the effect of E-4031 to a lesser extent, while empty liposomes vortexed with terfenadine did not alter its IKr inhibitory activity.
Conclusion: Curcumin causes an inhibition of the hERG tail current density. The liposomal curcumin formulation, as well as a mixture of empty liposomes with curcumin or with E-4031, blocked drug-induced IKr inhibition. However, empty liposomes mixed with terfenadine did not alter terfenadine’s IKr inhibitory effects. The liposomes protected against the inhibitory effect of some compounds on the K+-selective IKr current, independent of their potency.

Keywords: torsade de point, hERG, ion channel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]